UBS AM
DAWN

UBS AM’s Day One Biopharmaceuticals DAWN Stock Holding History

UBS AM’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.94M Buy
136,991
+12,569
+10% +$177K ﹤0.01% 1844
2025
Q4 		$1.16M Buy
124,422
+8,177
+7% +$68.3K ﹤0.01% 2092
2025
Q3 		$820K Sell
116,245
-59,171
-34% -$407K ﹤0.01% 2071
2025
Q2 		$1.14M Buy
175,416
+63,137
+56% +$434K ﹤0.01% 2355
2025
Q1 		$890K Buy
112,279
+36,700
+49% +$395K ﹤0.01% 2358
2024
Q4 		$958K Buy
75,579
+10,386
+16% +$145K ﹤0.01% 2380
2024
Q3 		$908K Sell
65,193
-4,537
-7% -$64.7K ﹤0.01% 2443
2024
Q2 		$961K Buy
69,730
+31,851
+84% +$466K ﹤0.01% 2386
2024
Q1 		$626K Buy
37,879
+23,579
+165% +$353K ﹤0.01% 2213
2023
Q4 		$209K Buy
+14,300
New +$173K ﹤0.01% 2485

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

UBS AM's DAWN Position: Q1 2026 in Review

UBS AM increased its Day One Biopharmaceuticals (DAWN) stake by 10% in Q1 2026, buying an estimated $177K and bringing the position to 136,991 shares worth $2.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1844.

UBS AM first reported a position in DAWN in Q4 2023 and has held it in 10 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • UBS AM held 136,991 shares of Day One Biopharmaceuticals worth $2.94M as of Q1 2026.
  • UBS AM bought 12,569 Day One Biopharmaceuticals shares in Q1 2026, an estimated $177K.
  • Day One Biopharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #1844 holding.
  • UBS AM first reported a position in Day One Biopharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.